secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001104659-23-001704
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome (IMNM) completes first cohort in Phase 1b COVID-19 antibody study; seeks partner
--------------------------------------------------------------------------------

- First cohort of Phase 1b study of IMM-BCP-01 (COVID-19 antibody cocktail) dosed with no significant treatment-related adverse events.
- Company plans to seek a partner to continue the trial and further development of IMM-BCP-01.
- Entered into a Letter Agreement with Whitehead Institute modifying payment obligations under a 2009 license agreement with a collaborator.
- Corporate presentation dated January 2023 posted on company website for investor and partner meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923001704/0001104659-23-001704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465923001704/tm231749d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-001704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer